CTRI/2020/06/025910
Completed
未知
Safety And Efficacy Of Sofosbuvir And Daclatasvir In Children And Adolescents With Thalassemia With Chronic HCV Infection A Pilot Study
Riten Kumar Samadder0 sites70 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: B182- Chronic viral hepatitis CHealth Condition 2: D56- Thalassemia
- Sponsor
- Riten Kumar Samadder
- Enrollment
- 70
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All Patients Of Chronic Hepatitis C In Thalassemic Patient With 6 To 18 Years of Age With Any Level Of Detectable HCV RNA Is To Be Included In The Study
- •Patients Could Be Either Treatment Naive Or Interferon Experienced
Exclusion Criteria
- •The Legal Guardians/Parents Of The Patients Who Are Not Willing To Give Written Consent
- •Patients Who Are HIV Positive
- •Patients Who Were HBsAg Positive
- •Patient With HCV RNA Below Detection Level At Entry To The Trial
- •Patient With Associated Tuberculosis Or Malignancy
- •Presence of Cirrhosis
- •Presence Of Any Major Comorbidities Like Heart Failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
Completed
Not Applicable
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.IRCT20170614034526N3Jinnah Hospital, Lahore36
Completed
Phase 3
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
Recruiting
Phase 1
Safety of Sofosbuvir /Daclatasvir in outpatients with COVID-19IRCT20200128046294N3Tehran University of Medical Sciences50
Completed
Phase 3
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000